Jabbour SK, Cho BC, Bria E, Kato T, et al. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer 2022 Apr 29. pii: S1525-7304(22)00066.
PMID: 35618629